【摘要】 目的探讨Galectin3,CK19及Ki-67在甲状腺乳头状癌与乳头状增生中的表达,寻找有助于两者鉴别诊断的标志物。方法运用免疫组化方法检测100例甲状腺乳头状癌、100例良性乳头状增生中Galectin3,CK19及Ki-67的表达。结果Galectin3,CK19及Ki-67在甲状腺乳头状癌阳性表达率分别为100%,97%及93%,而在乳头状增生中表达率分别为13%,30%及1%,3种蛋白在乳头状癌与良性乳头状增生间差异有统计学意义(P<0.05)。在乳头状癌中2种或3种蛋白同时阳性表达为94.3%,而乳头状增生为0。结论Galectin3,CK19及Ki-67是鉴别诊断甲状腺乳头状癌与乳头状增生的有用标志物,尤其联合使用更有价值。更多还原

【Abstract】 Objective To study the expression of Galectin-3,CK19 and Ki-67 in the papillary thyroid carcinoma and papillary thyroid hyperplasia and to find the differential diagnostic makers. Methods A total of 200 cases, including 100 with papillary thyroid carcinoma and 100 papillary thyroid hyperplasia by Immunohistochemistry. Results The positive rates for Galectin-3,CK19 and Ki-67 in the papillary thyroid carcinoma were 100 %, 97 % and 93 %, which were significantly higher than those in the papillary thyroid hyperplasia (13 %, 31 %, 1 %) (P < 0.05). The positive rate which two or three of the 3 makers in the papillary thyroid carcinoma were 94.3 %, and the positive rate which two or three of the 3 makers in the papillary thyroid hyperplasia were 0 %. Conclusion Galectin-3, CK19 and Ki-67 were useful makers to distinguish the papillary thyroid carcinoma from papillary thyroid hyperplasia, especially combined application.更多还原